To explore the clinical and prognostic value of fibroblast growth factor receptor 1 (FGFR1) mRNA expression and amplification in patients with esophageal squamous cell carcinoma (ESCC).
FGFR1 mRNA expression was measured by quantitative RT-PCR in tumor tissue of 145 Chinese patients with ESCC who underwent surgery during January 2009 and December 2010 in West China Hospital. Pooled data about FGFR1 mRNA expression, amplification and survival of 186 patients with Esophageal Carcinoma was extracted from TCGA database (TCGA, Provisional). Log rank and Cox proportional hazards regression were conducted to analyze the correlation between survival and FGFR1 mRNA expression or amplification.
Univariate analysis showed ESCC patients with higher FGFR1 mRNA expression had significantly shorter overall survival (OS: 22.00 vs 33.00 months; P =0.038) than those with lower FGFR1 mRNA expression. Multivariate modeling confirmed that patients with higher FGFR1 mRNA expression had a significantly greater risk of death than those with lower FGFR1 mRNA expression after adjusting for pathologic stage (hazard ratio [HR]= 1.54, 95 % confidence interval [CI] = 1.03–2.30, P = 0.037). However, the analysis of pooled data from TCGA indicates there is no significant association between FGFR1 mRNA expression and OS in ESCC patients (25.10 vs 25.07 months; P =0.477). Either in our local or TCGA data sets, no significantly correlation between FGFR1 mRNA expression and disease free survival (DFS) was found (21.10 vs 39.00 months, P =0.1413; 18.10 vs 21.22 months; P =0.334). Pooled analysis of TCGA datasets showed FGFR1 amplification was found in 13/186 (6.98 %) of all patients and was more frequent but without significant difference in squamous cell carcinoma than that in adenocarcinoma (10.31 % vs 3.37 %; P = 0.064). Survival analysis showed ESCC with FGFR1 amplification had no significantly difference in OS (25.47 v 35.80 months; P =0.499) than those without FGFR1 amplification.
Our analyses results support FGFR1 mRNA expression but not amplification could be an independent prognostic biomarker in patients with surgically resected ESCC.
Clinical trial identification
Legal entity responsible for the study
West China Hospital
All authors have declared no conflicts of interest.